+

WO2005076005A3 - A method for classifying a tumor cell sample based upon differential expression of at least two genes - Google Patents

A method for classifying a tumor cell sample based upon differential expression of at least two genes Download PDF

Info

Publication number
WO2005076005A3
WO2005076005A3 PCT/EP2005/000858 EP2005000858W WO2005076005A3 WO 2005076005 A3 WO2005076005 A3 WO 2005076005A3 EP 2005000858 W EP2005000858 W EP 2005000858W WO 2005076005 A3 WO2005076005 A3 WO 2005076005A3
Authority
WO
WIPO (PCT)
Prior art keywords
classifying
cell sample
tumor cell
genes
differential expression
Prior art date
Application number
PCT/EP2005/000858
Other languages
French (fr)
Other versions
WO2005076005A2 (en
Inventor
Christian Stratowa
Ulrich Koenig
Peter Steinlein
Stefan Amatschek
Herbert Auer
Wolfgang Sommergruber
Martin Schreiber
Agnes Gruenfelder
Margit Pacher-Zavisin
Original Assignee
Univ Wien Med
Christian Stratowa
Ulrich Koenig
Peter Steinlein
Stefan Amatschek
Herbert Auer
Wolfgang Sommergruber
Martin Schreiber
Agnes Gruenfelder
Margit Pacher-Zavisin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wien Med, Christian Stratowa, Ulrich Koenig, Peter Steinlein, Stefan Amatschek, Herbert Auer, Wolfgang Sommergruber, Martin Schreiber, Agnes Gruenfelder, Margit Pacher-Zavisin filed Critical Univ Wien Med
Publication of WO2005076005A2 publication Critical patent/WO2005076005A2/en
Publication of WO2005076005A3 publication Critical patent/WO2005076005A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Described is a method for classifying a cell sample as being a tumor cell comprising detecting a difference in the expression by said cell sample of at least one gene of Table 4 relative to at least one control cell and classifying the cell sample as a tumor cell, if the at least one gene of Table 4 shows at least 1,5-fold higher expression than the control cell.
PCT/EP2005/000858 2004-01-30 2005-01-28 A method for classifying a tumor cell sample based upon differential expression of at least two genes WO2005076005A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04450020 2004-01-30
EP04450020.5 2004-01-30

Publications (2)

Publication Number Publication Date
WO2005076005A2 WO2005076005A2 (en) 2005-08-18
WO2005076005A3 true WO2005076005A3 (en) 2009-02-05

Family

ID=34833853

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/000858 WO2005076005A2 (en) 2004-01-30 2005-01-28 A method for classifying a tumor cell sample based upon differential expression of at least two genes

Country Status (1)

Country Link
WO (1) WO2005076005A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107312854A (en) * 2017-07-20 2017-11-03 北京泱深生物信息技术有限公司 A kind of diagnosis marker and its therapeutic targets of larynx squamous carcinoma

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
NZ593228A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (inhba) for colorectal cancer prognosis
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
US8765383B2 (en) 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
WO2010127322A1 (en) 2009-05-01 2010-11-04 Genomic Health Inc. Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
MX359416B (en) 2010-07-27 2018-09-27 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer.
US8852592B2 (en) 2011-05-10 2014-10-07 Biocare Medical, Llc Systems and methods for anti-PAX8 antibodies
EP3179393B1 (en) 2012-01-31 2020-07-08 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
EP2900265B1 (en) 2012-09-27 2018-05-30 Biocare Medical, LLC Anti-uroplakin ii antibodies systems and methods
US10429390B2 (en) 2012-12-18 2019-10-01 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
JP6445467B2 (en) 2013-02-28 2019-01-09 バイオケア メディカル， エルエルシー Anti-P40 antibody system and method
WO2015051320A2 (en) 2013-10-03 2015-04-09 Biocare Medical, Llc Anti-sox10 antibody systems and methods
IT201700109459A1 (en) * 2017-09-29 2019-03-29 Univ Degli Studi Di Perugia METHOD TO PERFORM PROGNOSIS OF BREAST CANCER, KITS AND THE USE OF THESE
CN111159409B (en) * 2019-12-31 2023-06-02 腾讯科技（深圳）有限公司 Text classification method, device, equipment and medium based on artificial intelligence
CN112816431A (en) * 2020-09-22 2021-05-18 西华师范大学 Dual-wavelength capillary electrophoresis detection system for detecting tumor marker
CN112575085B (en) * 2020-12-22 2025-04-25 复旦大学附属华山医院 Gene expression profiling for prognosis in adrenocortical carcinoma
CN117594133A (en) * 2024-01-19 2024-02-23 普瑞基准科技（北京）有限公司 Screening method of biomarker for distinguishing uterine lesion type and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074405A1 (en) * 2000-03-31 2001-10-11 Gene Logic, Inc. Gene expression profiles in esophageal tissue
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074405A1 (en) * 2000-03-31 2001-10-11 Gene Logic, Inc. Gene expression profiles in esophageal tissue
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AMATSCHEK STEFAN ET AL: "Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific gene.", CANCER RESEARCH, vol. 64, no. 3, 1 February 2004 (2004-02-01), pages 844 - 856, XP001206325, ISSN: 0008-5472 *
CHANG K ET AL: "FREQUENT EXPRESSION OF THE TUMOR ANTIGEN CAK1 IN SQUAMOUS-CELL CARCINOMAS", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 51, no. 4, 19 June 1992 (1992-06-19), pages 548 - 554, XP002038952, ISSN: 0020-7136 *
HUDELIST GERNOT ET AL: "Use of high-throughput protein array for profiling of differentially expressed proteins in normal and malignant breast tissue.", BREAST CANCER RESEARCH AND TREATMENT. AUG 2004, vol. 86, no. 3, August 2004 (2004-08-01), pages 281 - 291, XP001206326, ISSN: 0167-6806 *
NEMOTO TETSUO ET AL: "Overexpression of protein tyrosine kinases in human esophageal cancer", PATHOBIOLOGY, vol. 65, no. 4, July 1997 (1997-07-01), pages 195 - 203, XP009048170, ISSN: 1015-2008 *
SÁNCHEZ-CARBAYO MARTA: "Use of high-throughput DNA microarrays to identify biomarkers for bladder cancer.", CLINICAL CHEMISTRY. JAN 2003, vol. 49, no. 1, January 2003 (2003-01-01), pages 23 - 31, XP001206327, ISSN: 0009-9147 *
VAN HEEK N TJARDA ET AL: "Gene expression profiling identifies markers of ampullary adenocarcinoma.", CANCER BIOLOGY & THERAPY. JUL 2004, vol. 3, no. 7, July 2004 (2004-07-01), pages 651 - 656, XP009048026, ISSN: 1538-4047 *
WU L ET AL: "MOLECULAR CLONING OF THE HUMAN CAK1 GENE ENCODING A CYCLIN-DEPENDENT KINASE-ACTIVATING KINASE", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 9, no. 7, 1 July 1994 (1994-07-01), pages 2089 - 2096, XP000673011, ISSN: 0950-9232 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107312854A (en) * 2017-07-20 2017-11-03 北京泱深生物信息技术有限公司 A kind of diagnosis marker and its therapeutic targets of larynx squamous carcinoma

Also Published As

Publication number Publication date
WO2005076005A2 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
WO2005076005A3 (en) A method for classifying a tumor cell sample based upon differential expression of at least two genes
WO2006073445A3 (en) Detection and typing of bacterial strains
WO2005084305A3 (en) Flavonoids
WO2007047680A3 (en) Increasing the activity of radical s-adenosyl methionine (sam) enzymes
WO2006089091A3 (en) Methods for detecting minimum residual disease
WO2004007675A3 (en) Neuronal and optic nerve gene expression patterns
WO2004074425A3 (en) Method and device for the formation of biological cell material
WO2009075799A3 (en) Method for diagnosing lung cancers using gene expression profiles in peripheral blood mononuclear cells
WO2008100892A3 (en) Fungal endophytes of elymus canadensis
WO2008118392A3 (en) Synthetic cell platforms and methods of use thereof
WO2006091924A3 (en) Producing carotenoids
WO2002046465A3 (en) Method for identification of genes involved in specific diseases
WO2007002762A3 (en) Components of cell culture media produced from plant cells
WO2006071466A3 (en) Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders
EP1363125A3 (en) Transcription factor profiling on a solid surface
WO2005054517A3 (en) Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders
WO2007031949A3 (en) Liquid media for chlamydospore production of the fungus pochonia chlamydosporia
WO2005087951A3 (en) Reagents, methods and kits for use in deactivating nucleic acids
WO2009030770A3 (en) Methods and tools for prognosis of cancer in er- patients
WO2006017751A3 (en) Methods for the detection of molecular interactions within cells
WO2008011379A3 (en) Oxidized apoa1 determination by mass spectrometry
WO2006072078A3 (en) Bioproduction of astaxanthin using mutant carotenoid ketolase and cartonenoid hydroxylase genes
WO2005054439A3 (en) Small interfering rna (sirna)-mediated heritable gene manipulation in plants
WO2006004728A3 (en) Cell culture medium comprising transition metals or trace elements
WO2004072225A3 (en) Transgenic fungi expressing bcl-2 and methods of using bcl-2 or portions thereof for improving biomass production, survival, longevity, stress resistance and pathogenicity of fungi

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载